Literature DB >> 21812699

Diagnosis of smoldering multiple myeloma.

S Vincent Rajkumar, Dirk Larson, Robert A Kyle.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21812699      PMCID： PMC3773467          DOI： 10.1056/NEJMc1106428

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

Review 2.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

3.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245
  3 in total
  40 in total

1.  Haematological cancer: Treatment of smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Robert A Kyle
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

2.  Classifying ultra-high risk smoldering myeloma.

Authors:  A J Waxman; R Mick; A L Garfall; A Cohen; D T Vogl; E A Stadtmauer; B M Weiss
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

Review 3.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

4.  Haematological cancer: Redefining myeloma.

Authors:  S Vincent Rajkumar; Giampaolo Merlini; Jesus F San Miguel
Journal:  Nat Rev Clin Oncol       Date:  2012-07-31       Impact factor: 66.675

Review 5.  The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Authors:  Jo Caers; Carlos Fernández de Larrea; Xavier Leleu; Roy Heusschen; Niklas Zojer; Olivier Decaux; Efstathios Kastritis; Monique Minnema; Artur Jurczyszyn; Yves Beguin; Ralph Wäsch; Antonio Palumbo; Meletios Dimopoulos; Maria Victoria Mateos; Heinz Ludwig; Monika Engelhardt
Journal:  Oncologist       Date:  2016-02-26

Review 6.  Diagnostic Advances in Multiple Myeloma.

Authors:  Kevin Barley; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

7.  The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma.

Authors:  E Kastritis; L A Moulopoulos; E Terpos; V Koutoulidis; M A Dimopoulos
Journal:  Leukemia       Date:  2014-07-31       Impact factor: 11.528

8.  Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Authors:  Vernon Wu; Erin Moshier; Siyang Leng; Bart Barlogie; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Madhu Mazumdar; Samir Parekh; Ajai Chari
Journal:  Blood Adv       Date:  2018-06-26

Review 9.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

10.  Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.

Authors:  W I Gonsalves; S V Rajkumar; A Dispenzieri; D Dingli; M M Timm; W G Morice; M Q Lacy; F K Buadi; R S Go; N Leung; P Kapoor; S R Hayman; J A Lust; S J Russell; S R Zeldenrust; L Hwa; T V Kourelis; R A Kyle; M A Gertz; S K Kumar
Journal:  Leukemia       Date:  2016-07-26       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.